Effect of SARS-CoV-2 Infection on the Microbial Composition of Upper Airway

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Zhenguo Wang^{1,*}
Xiaojun Hu^{2,*}
Zhonghe Li^{3,*}
Changli Tu¹
Yiming Wang⁴
Pengfei Pang²
Huitao Zhang^{2,*}
Xiaobin Zheng¹
Yingjian Liang¹
Hong Shan²
Jing Liu¹

¹Department of Pulmonary and Critical Care Medicine (PCCM), The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, People's Republic of China; ²Department of Center for Interventional Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, People's Republic of China; ³Department of Nephrology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, People's Republic of China; ⁴Department of Huada Joint Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, People's Republic of China

*These authors contributed equally to this work

Correspondence: Jing Liu; Hong Shan
Fifth Affiliated Hospital of Sun Yat-sen University, 52 East Meihua Road, Zhuhai City 519000, People's Republic of China
Tel +86 7562528538
Email liujing25@sysu.edu.cn;
hongshanzdwy@163.com

Methods: Forty-four COVID-19 patients (severe/critical: N = 8, non-severe: N = 36) were examined by next generation sequencing (NGS) of nasopharyngeal test paper to observe the effect of novel coronavirus infection to the microbial composition in upper airway.

Results: In these nasopharyngeal test paper samples, 38 kinds of bacteria, 10 kinds of viruses except *SARS-CoV-2*, nine kinds of fungi and three kinds of atypical pathogens had been found. There was some difference in microbial composition in the upper airway between severe and non-severe cases.

Summary: These results are important for us to study the effect of *SARS-CoV-2* on the local microbial composition of upper airway and prevent opportunistic infection in severe patients.

Keywords: *SARS-CoV-2*, microbial composition, upper airway, next generation sequencing; NGS

Introduction

By April 24, 2020, there were 2,626,321 confirmed and 181,938 deaths cases of COVID-19 globally.¹ It is important that understood the effect of novel coronavirus on microbial composition on invaded mucosa for avoiding secondary infection. In recent year, next generation sequencing (NGS) technologies provide an increasingly important method for detecting microbial composition and pathogen in human.²

Methods

In our hospital, 44 novel coronavirus infection patients (severe/critical: N = 8, non-severe: N = 36) were examined by NGS of nasopharyngeal test paper to observe the effect of novel coronavirus infection on the microbial composition in upper airway. And the demographics and clinical characteristics of these 44 COVID-19 patients were collected and analyzed. The DNA libraries were sequencing using the BGISEQ-100 platform from The Beijing Genomics Institute. Species information of suspected pathogenic microorganisms can be obtained through comparison of microbial database and intelligent algorithm analysis. We can identify 12,593 pathogenic microorganisms including bacteria, fungi, viruses, parasites, mycoplasma/chlamydia accurately. Statistical analysis was performed using Statistical Package for Social Science (SPSS) Version 17.0. Measurement data was expressed as mean $\pm$ standard deviation. Continuous variables were compared using independent-sample *t*-test, whereas the rank sum test was used for nonparametric data. *P* < 0.05 was considered statistically significant.

Results

Demographics and Clinical Characteristics of COVID-19 Patients

Compared with non-severe patients, older of age, higher proportion of fever and fatigue, more basic diseases, more involved lung leaves, lower white blood cells, lower lymphocytes, decreased CD3 + T cells and subsets groups, but increased CRP were shown in severe/critical patients ($P < 0.05$, Table 1). Specially, decreased CD3 + T cells

and subsets groups were risk factors for secondary infection.

The Microbial Composition of Upper Airway in COVID-19 Patients

In these nasopharyngeal test paper samples, 38 kinds of bacteria, 10 kinds of viruses except severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), nine kinds of fungi and three kinds of atypical pathogens had been found. The

Table 1 Demographics and Clinical Characteristics of COVID-19 Patients

Characteristic	Total (n = 44)	Severe/Critical (n = 8)	Non-Severe (n = 36)	p value
Age, years	54(3–77)	62.5(54–77)	44(3–71)	0.008*
Gender Male	21(47.7)	5(62.5)	16(44.4)	0.35
Female	23(52.3)	3(37.5)	20(45.6)	
Signs and symptoms				
Fever	29(65.9)	7(87.5)	22(61.1)	0.15
Cough	18(40.9)	3(37.5)	15(41.7)	0.83
Fatigue	5(11.4)	3(37.5)	2(5.5)	0.01*
Nasal discharge	2(4.5)	0(0)	2(5.5)	0.49
Pain (headache/sore throat/muscle aches, etc)	9(20.4)	2(25)	7(19.4)	0.72
T, °C	37.0(36.5–37.8)	37.7(37.3–38.0)	36.8(36.5–37.7)	0.04*
Underlying diseases(N/Y)	16(36.4)	5(62.5)	11(30.5)	0.09
Circulatory diseases (hypertension, coronary heart disease)	7(15.9)	2(25)	5(13.9)	0.44
Respiratory basic diseases (chronic bronchitis, lung cancer)	3(6.8)	2(25)	1(2.8)	0.02*
Endocrine system basic diseases (diabetes)	3(6.8)	2(25)	1(2.8)	0.02*
Other systemic diseases (fractures, cerebral infarction, etc.)	5(11.4)	1(12.5)	4(11.1)	0.91
Laboratory findings				
White blood cell count, $\times 10^9/L$	4.61(3.67–6.48)	3.52(3.14–4.59)	4.82(3.83–6.56)	0.04*
Lymphocyte count, $\times 10^9/L$	1.60 (1.08–2.13)	0.85(0.45–1.46)	1.76(1.36–2.46)	0.001*
Neutrophil count, $\times 10^9/L$	2.30(1.79–3.47)	2.08(1.30–3.34)	2.36(1.88–3.61)	0.38
Monocyte count, $\times 10^9/L$	0.47(0.37–0.66)	0.34(0.26–0.52)	0.49(0.40–0.71)	0.06
NLR	1.78(0.4–9.38)	2.16(0.74–9.38)	1.70 (0.40–5.68)	0.025*
PCT	2(4.5)	1(12.8)	1(2.8)	0.23
CRP, mg/L	2.45(0.56–7.62)	22.0(8.68–42.5)	1.15(0.48–5.06)	0.001*
CD3(+) T lymphocytes, μl	1057(742.8–1561)	565 (226.0–794.5)	1162(891.3–1734)	0.001*
CD3(+)CD4(+) T lymphocytes, μl	579(408.3–831.5)	325(174.5–483.8)	631.5(449.8–842.5)	0.006*
CD3(+)CD8(+) T lymphocytes, μl	355(263.8–514.5)	159(64.5–281.8)	457.5(318.8–553.0)	0.0002*
PaO ₂ , mmHg	99.9(86.6–105.0)	91.1(75.7–101.2)	101.0(89.1–105.3)	0.12
CT imaging features				
One or both lungs	2(0–2)	2(1–2)	1(0–2)	0.02*
Number of lung lobes (0–5)	2next (0–5)	5(1–5)	1(0–5)	0.001*
Ground glass lesions	29(65.9%)	7(87.5%)	22(61.1%)	0.15
Consolidation	7(15.9%)	3(37.5%)	4(11.1%)	0.06
Bronchial abnormalities	4(9.1%)	2(25%)	2(5.5%)	0.08
Mediastinal lymph node enlargement	1(2.3%)	1(12.5%)	0(0)	0.04*
Pleural effusion	1(2.3%)	1(12.5%)	0(0)	0.04*

Note: * $P < 0.05$.

Abbreviations: T, temperature; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin; CRP, C-reactive protein; PaO₂, arterial partial pressure of oxygen.

Figure 1 The microbial composition of upper airway in patients with SARS-CoV-2 infection.

Notes: The percentage of cases with different kinds of bacteria (A), virus (B), fungus and atypical pathogens (C) detected by next generation sequencing of nasopharyngeal test paper was shown in this figure. * $P < 0.05$, there was significant difference between severe and non-severe groups.

most common bacteria detected in upper airway in these patients were *Haemophilus* (40.9%), *Corynebacterium* (40.9%), *Prevotella* (36.36%), *Staphylococcus* (34.09%), *Moraxella* (22.72%), *Neisseria* (22.72%), *Streptococcus* (20.45%), *Megaphaera* (20.45%), *Pediococcus* (18.18%), and *Dolosigranulum* (15.91%) (Figure 1A). *Human herpes virus* and *Torque teno virus* were the main viruses detected in nasopharyngeal test paper, but no *Influenza virus* was found. The most common viruses were *Human gamma herpesvirus 4* (38.6%) and *Human beta herpesvirus 7* (38.6%), and the other viruses were less than 10% (Figure 1B). *Candida* (36.36%) was the main fungus found in upper airway of patients, and *Aspergillus* was detected in one case of severe and one case of non-severe patients respectively. *Mycoplasma* was shown in 36.36% of all patients (Figure 1C). There was some difference in microbial composition in upper airway between severe and non-severe cases. In non-

severe patients, the proportion of *Corynebacterium* was higher (47.22% vs. 12.5%) (Figure 1A), while *Human gamma herpesvirus 4* was lower (30.55% vs. 75%) (Figure 1B), compared with severe ones. *SARS-CoV-2* declined types of bacteria but increased types of other viruses in upper airway in severe COVID-19 patients in a way.

Discussion

The influence of the *SARS-CoV-2* on the microbial environment of airway mucosa is not clear. Due to the highly infectious characteristics of *SARS-CoV-2*, it is difficult to obtain the secretion samples from lower airway. There are many common normal parasitic bacteria in the upper respiratory tract. Common bacteria have *aureus*, *coagulase negative staphylococcus*, *pulmonary chain*, *group A streptococcus*, *enterococcus*, *neisseria meningitis*, *diphtheria corynebacterium* and so on. And the common

fungus is *Candida albicans*.³ We studied the influence of SARS-CoV-2 on the microbial environment of upper airway mucosa by analyzing the microbial composition of upper respiratory tract of COVID-19 patients. Particularly for severe/critical patients, in which lymphocyte declining and immune function inhibition are obvious, we should pay more attention to some opportunistic infections. For example, combining infection of *Human gamma herpesvirus 4* had been found both in nasopharyngeal test paper and blood samples of 2 critical patients by NGS, accompanying with *SARS-CoV-2* infection.

Abbreviations

COVID-19, 2019 coronavirus disease; NGS, next generation sequencing; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; T, temperature; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin; CRP, C-reactive protein; PaO₂, arterial partial pressure of oxygen.

Consent for Publication

Written informed consent for publication was obtained from all participants.

Ethics Approval and Consent to Participate

This retrospective observational study was approved by the Research Ethics Committee of The Fifth Affiliated Hospital of Sun Yat-sen University (approval series

number K30-1) and the need for informed consent was waived, considering the retrospective study design. We will keep all patient data confidential and strictly comply with the Declaration of Helsinki.

Acknowledgment

We would like to extend gratitude to BGI.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors declare that they have no conflicts of interest in this work.

References

1. Novel coronavirus (2019-nCoV). Situation report-95. WHO. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>. Accessed April 24, 2020.
2. Cantalupo PG, Pipas JM. Detecting viral sequences in NGS data. *Curr Opin Virol*. 2019;39:41–48. doi:10.1016/j.coviro.2019.07.010
3. Benninger M, Brook I, J M B, et al. Bacterial interference in upper respiratory tract infections: a systematic review. *Am J Rhinol Allergy*. 2011;25(2):82–88. doi:10.2500/ajra.2011.25.3594

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress